X4 Pharmaceuticals, Inc., formerly Arsanis, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases including primary immunodeficiencies and cancer. The Company’s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. Its product candidates include X4P-001, X4P-002 and X4P-003.
http://www.x4pharma.com/© 2026 J2T Services Ltd
J2T Services Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by J2T SERVICES LTD.
Registration Number: HE 341520
Address: J2T Services Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
E-mail: 24_support@j2t.com
